retatrutide nash Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial retatrutide nonalcoholic fatty liver disease

No other approved obesity medication activates glucagon receptors at meaningful levels

RETA treatment improved metabolic factors, boosted anti-tumor immunity, and potently blunted tumor progression in non-obesity associated lung adenocarcinoma Based on the dramatic findings in PDAC, an obesity-associated cancer, we were interested in whether RETA could also be effective in a non-obesity associated cancer

24hrDOC offers convenient access to effective weight loss medications like oral semaglutide, semaglutide injection, and tirzepatide through our secure telehealth platform

TrimRx provides access to compounded semaglutide at $199/month and compounded tirzepatide at $349/monthboth with licensed medical oversight, FDA-registered pharmacy partners, and proven results